Dingwei Ye, Bo Dai, Weijie Gu, Shusuan Jiang, Hong Luo, Fang-Jian Zhou, Dalin He, Lulin Ma, Hongqian Guo, Chaochao Liang, Tie Chong, Jun Zhang, Zhiwen Chen, Yong Wang, Qing Zou, Ye Tian, Jun Xiao, Xinfeng Yang, Jianpo Lian, Wenliang Wang. "Rezvilutamide (Rez) versus bicalutamide (Bic) plus androgen-deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC): 5-year outcomes of the phase 3 CHART trial.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.5090